Monash University Study Highlights Critical Role of Third COVID-19 Dose in Immunocompromised Protection
A groundbreaking Australian-first study from Monash University has demonstrated that a third dose of COVID-19 vaccine is essential for eliciting meaningful long-term immune protection in patients with inborn errors of immunity (IEI), also known as primary immunodeficiencies. These rare genetic disorders impair the immune system's ability to fight infections, leaving affected individuals at significantly heightened risk from diseases like COVID-19. Led by Dr. Emily S.J. Edwards from the Monash School of Translational Medicine, the research reveals that even when traditional markers like neutralizing antibodies are absent, adaptive immune memory—through memory B cells and T cells—provides crucial defense mechanisms.
The findings, detailed in a preprint published on medRxiv and recently highlighted in the Journal of Allergy and Clinical Immunology, underscore Monash's leadership in immunology research amid ongoing challenges with SARS-CoV-2 variants. With immunocompromised Australians facing up to four times the hospitalization risk from COVID-19, this work informs tailored vaccination strategies vital for public health equity.
Understanding Inborn Errors of Immunity: A Primer on IEI
Inborn errors of immunity (IEI) encompass over 500 identified genetic defects that disrupt immune function, affecting approximately 1 in 1,000 to 2,000 people in Australia. These conditions range from antibody deficiencies like common variable immunodeficiency (CVID) to combined immunodeficiencies impacting both B and T cells. Patients often experience recurrent infections, autoimmunity, and poor vaccine responses, making COVID-19 particularly dangerous.
Monash researchers focused on 25 adults with IEI, comparing their responses to 29 healthy controls. IEI prevalence in Australia is estimated at around 15,000-30,000 individuals, highlighting the study's relevance. Early in the pandemic, standard two-dose regimens proved inadequate for this group, prompting Australian Technical Advisory Group on Immunisation (ATAGI) guidelines recommending a third primary dose for severely immunocompromised persons.
Study Design and Methodology: Rigorous Analysis of Vaccine-Induced Immunity
The Monash-led investigation collected blood samples one month after the second and third doses. Participants received either mRNA vaccines (Pfizer BNT162b2 or Moderna mRNA-1273) or a primary adenoviral vector (ChAdOx1) followed by mRNA boosters as the third dose. Advanced assays measured neutralizing antibodies (NAb) via live virus neutralization, Spike receptor-binding domain (RBD)-specific IgG via ELISA (targeting ancestral Wuhan-Hu-1, Omicron BA.2, and BA.5), memory B cells using fluorescent tetramers, and T cell responses through flow cytometry assessing activation markers (CD69, CD134, CD137) and cytokines (IFN-γ, TNF-α).
This comprehensive approach went beyond serology, capturing cellular immunity often overlooked in immunocompromised assessments. Funded partly through the PROPHECY consortium—a Medical Research Future Fund (MRFF) initiative—the study exemplifies collaborative Australian higher education efforts involving Monash, Burnet Institute, Alfred Hospital, and Monash Health.
Key Findings: Third Dose Bridges the Immunity Gap
Post-second dose, only 16% of IEI patients had detectable NAb compared to 87% of controls, with similarly diminished RBD-specific IgG and memory B cells. The third dose dramatically improved outcomes: NAb seroconversion rose to 64%, IgG levels boosted significantly, and memory B cells increased 2.7-fold (versus 4-fold in controls). Strikingly, among 9 patients without NAb post-third dose, all produced Spike-specific IgG, and most exhibited memory B or T cell responses.
T cell numbers were comparable between groups, but IEI patients showed qualitative deficits like reduced cytokine co-expression. Omicron-specific responses lagged, emphasizing variant challenges. These results affirm that the third dose activates 'hidden' protection layers, challenging notions of vaccine 'failure' based solely on antibodies. For full details, see the medRxiv preprint.
Implications for Australian Vaccination Policy and ATAGI Guidelines
Australia's ATAGI continues to advocate a three-dose primary series for severely immunocompromised individuals, with boosters every 6-12 months based on risk. This Monash study validates that approach, showing the third dose as primary enhances memory formation, reducing severe COVID-19 risks. In 2026, with evolving variants, universities like Monash are pivotal in updating these policies through evidence.
Broader immunocompromised groups—cancer patients, transplant recipients—affect over 5% of Australians. The research supports personalized regimens, potentially integrating cellular immunity assays into clinical practice. Collaborations via PROPHECY ensure pediatric extensions, addressing lifelong vulnerabilities.
Monash University's Pivotal Role in Immunology and COVID Research
Monash University's School of Translational Medicine, home to Dr. Edwards' Primary Immunodeficiencies Group, spearheads IEI research. Edwards, an Honorary Senior Research Fellow at Burnet Institute, builds on prior COVID studies like BOOST-IC—an adaptive trial optimizing boosters for immunocompromised hosts (ICH). This MRFF-backed platform tests one- or two-dose regimens across Australian sites.
Monash's immunotherapy expertise, including mRNA vaccine development, positions it as a hub for vaccine innovation. Partnerships with Alfred Health and Jeffrey Modell Foundation centers amplify impact, training next-gen immunologists amid Australia's higher education push for translational research.
Stakeholder Perspectives: Experts Weigh In on the Findings
Dr. Edwards emphasized: "This research is critical to deliver personalised treatment regimes... vaccine boosters remain critical for people with immune disorders." Co-authors from Burnet and Monash Health highlight cellular immunity's role, urging beyond-antibody monitoring.
Australian Society of Clinical Immunology and Allergy (ASCIA) aligns, noting IEI's diagnostic delays. Health departments praise PROPHECY's $6.3M MRFF funding for vulnerable profiling. For insights, read the Mirage News coverage.
Challenges and Future Directions in Immunocompromised Vaccination
Despite gains, Omicron responses remain suboptimal, signaling need for variant-updated boosters. BOOST-IC addresses this, evaluating bivalent vaccines. Monash eyes multi-omic profiling for predictors of response.
Australia's 2026 COVID landscape—waning population immunity—amplifies urgency. Universities drive solutions: gene therapies for IEI, nasal vaccines. Challenges include access equity in regional areas and trial recruitment.
Real-World Impact: Case Studies and Australian Statistics
In Victoria, IEI clusters strain services; Monash's work reduces hospitalizations. Nationally, COVID claimed disproportionate immunocompromised lives pre-boosters. Post-third dose, modeled reductions exceed 50% severe cases.
- IEI hospitalization risk: 4x higher
- Third dose NAb boost: 4x from dose 2
- Memory cells in all patients: 100%
ATAGI's handbook details dosing; see Australian Immunisation Handbook.
Broader Contributions from Australian Higher Education
Beyond Monash, Doherty Institute and Murdoch University advance mRNA candidates tackling immune imprinting. Universities foster interdisciplinary teams, securing MRFF grants. This ecosystem positions Australia as a vaccine research leader.
For careers in this field, explore Monash's immunology programs driving discoveries.
Photo by julien Tromeur on Unsplash
Outlook: Sustaining Momentum in Vaccine Research
As SARS-CoV-2 evolves, Monash's findings advocate ongoing boosters and monitoring. Future trials integrate T/B cell metrics, promising equity. Australian unis must prioritize IEI amid funding pressures, ensuring vulnerable thrive.
.jpg&w=128&q=75)
